Zhongzhi Pharmaceutical Holdings Limited reported no changes to its share capital structure for the month ended 31 March 2026, according to its latest monthly return submitted to Hong Kong Exchanges and Clearing Limited on 1 April 2026.

The company’s authorised share capital remained at 1.56 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 15.60 million. Issued shares were unchanged at 863.60 million, and the issuer continued to hold zero treasury shares.

Zhongzhi Pharm confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent, ensuring sufficient market liquidity.

No share options, warrants, convertible securities, or other equity-linked instruments were issued or outstanding during the month, and there were no share repurchases, cancellations, or other movements affecting the capital base.

The filing was authorised by Director Lai Zhi Tian, affirming adherence to all relevant Hong Kong listing rules and regulatory obligations.